EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, vol.6, no.1, pp.59-63, 2022 (ESCI)
Objectives: Although immune checkpoint inhibitors (ICIs) became a vital part of cancer care, many patients do not respond to treatment. In this group, a few of the patients with a hyperprogressive disease (HPD) have shorter overall survival (OS) compared with those having a progressive disease (PD). Therefore, biomarkers are needed to differentiate HPD and PD.